Heat shock proteins (HSPs) such as gp96 are released from cells as a result of necrotic cell death. The ability of endogenous HSPpeptide complexes to elicit antigen-specific T cells requires representation of the chaperoned peptides by antigen-presenting cells. Re-presentation requires the uptake of HSP-peptide complexes through a receptor, suggested to be the low-density lipoprotein receptor-related protein or CD91. We have used short interfering RNA for CD91 to show that, as antigen-presenting cells lose expression of CD91, their re-presenting ability undergoes a corresponding and dramatic decline. Furthermore, as the cells recover from extinction of CD91 expression, they regain the ability to re-present peptides. The ability of cells to bind ␣2 macroglobulin, a previously known CD91 ligand, or HSP gp96, and their ability to process peptides chaperoned by ␣2 macroglobulin, undergo identical variations. These results have been obtained from studies in vitro and from an assay that measures re-presentation in vivo. In additional studies in vivo, protective tumor immunity elicited by tumor-derived gp96 -peptide complexes is shown to be abrogated by anti-CD91 antisera. These studies show that CD91 is essential for re-presentation of gp96-chaperoned peptides by MHC molecules and have an important bearing on the mechanism of immunogenicity of necrotic cells.heat shock proteins ͉ tumor immunity ͉ ␣2-macroglobulin ͉ receptor-associated protein ͉ LRP H eat shock proteins (HSPs) purified from antigen-expressing cells chaperone antigenic peptides generated in that cell (1-4). Immunization with such HSP-peptide complexes purified from tumors or pathogen-infected cells elicits specific immunity directed against the tumor or pathogen, respectively (5-7). The mechanism of immunogenicity of HSP-peptide complexes is increasingly clear. The HSP-peptide complex is targeted to the antigen-presenting cells (APCs) through interaction of HSP with a receptor identified as CD91 (8,9). In case of the HSP gp96, it appears that the HSP-peptide complex is endocytosed into a compartment positive for Fc receptor and MHC I and negative for Rab5a, CD1, and transferrin (10). The subsequent fate of the HSP molecule itself remains unclear, but the peptide is transported to the cytosol through a mechanism yet to be determined. The peptide is further transported into the endoplasmic reticulum through a transporterassociated with antigen processing-dependent (9, 11) or -independent (see refs. 11 and 12) mechanism. Following a classical pathway within the endoplasmic reticulum, the peptide is charged onto a cognate MHC I molecule, and the MHC I-peptide complex present at the cell surface now stimulates cognate CD8 ϩ T cells. Because the endocytosed HSP-peptide complex is taken up into a compartment that is MHC I ϩ (10), the possibility that the gp96-chaperoned peptide is charged onto the MHC I in that compartment, independently of the endoplasmic reticulum, merits consideration.Among the several HSPs that follow this path, the endoplasmic reticulum-r...